2023
Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer
Moutafi M, Koliou G, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Kyrodimos E, Delides A, Giotakis E, Papadimitriou N, Panayiotides I, Perisanidis C, Fernandez A, Xirou V, Poulios C, Gagari E, Yaghoobi V, Gavrielatou N, Shafi S, Aung T, Kougioumtzopoulou A, Kouloulias V, Palialexis K, Gkolfinopoulos S, Strati A, Lianidou E, Fountzilas G, Rimm D, Foukas P, Psyrri A. Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer. Cancer Research Communications 2023, 3: 1514-1523. PMID: 37575280, PMCID: PMC10414130, DOI: 10.1158/2767-9764.crc-23-0051.Peer-Reviewed Original ResearchConceptsObjective response rateTumor microenvironmentPD-L1Operable headResponse rateDeath ligand 1 (PD-L1) levelsPathologic complete response ratePhase II window studyNeck squamous cell carcinomaPD-L1 CPSComplete response rateSerious adverse eventsPercentage of patientsInhibitor-based treatmentSquamous cell carcinomaEffective antitumor responseImmunosuppressive tumor microenvironmentInflammatory tumor microenvironmentTumor cell proliferationColony-stimulating factor 1 receptor (CSF1R) genePrimary endpointSecondary endpointsAdverse eventsOpportunity trialAntitumor response
2019
A New Strategy for Identifying Mechanisms of Drug-drug Interaction Using Transcriptome Analysis: Compound Kushen Injection as a Proof of Principle
Shen H, Qu Z, Harata-Lee Y, Cui J, Aung TN, Wang W, Kortschak RD, Adelson DL. A New Strategy for Identifying Mechanisms of Drug-drug Interaction Using Transcriptome Analysis: Compound Kushen Injection as a Proof of Principle. Scientific Reports 2019, 9: 15889. PMID: 31685921, PMCID: PMC6828681, DOI: 10.1038/s41598-019-52375-3.Peer-Reviewed Original ResearchConceptsTranscriptome analysisCompound Kushen InjectionCo-expression analysisPotential targetPotential molecular mechanismsTranscriptome dataImportant genesMDA-MB-231 cellsProof of principlePhenotype resultsMolecular mechanismsCytotoxic effectsMetabolic processesMajor regulatorA431 cellsAntagonistic cytotoxic effectsKushen InjectionDNA synthesisCancer cellsInhibition of MyD88GenesComplex herbal mixturesMyD88 geneChemotherapy drugsCancer chemotherapy drugsFractional Deletion of Compound Kushen Injection Indicates Cytokine Signaling Pathways are Critical for its Perturbation of the Cell Cycle
Aung TN, Nourmohammadi S, Qu Z, Harata-Lee Y, Cui J, Shen HY, Yool AJ, Pukala T, Du H, Kortschak RD, Wei W, Adelson DL. Fractional Deletion of Compound Kushen Injection Indicates Cytokine Signaling Pathways are Critical for its Perturbation of the Cell Cycle. Scientific Reports 2019, 9: 14200. PMID: 31578346, PMCID: PMC6775143, DOI: 10.1038/s41598-019-50271-4.Peer-Reviewed Original ResearchConceptsCompound Kushen InjectionExperimental biology approachesEffect of CKIPlant secondary metabolitesCytokine Signaling PathwaysCKI activityBiology approachReconstitution approachGene expressionCell cyclePhenotype dataSignaling pathwaysSecondary metabolitesBreast cancer cell linesCancer cell linesKushen InjectionSingle major compoundCell linesApoptosisLiquid chromatography fractionationCell viabilityHigh-performance liquid chromatography fractionationMajor compoundsComplex fashionCandidate mechanismYiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung T, Qu Z, Chen Z, Adelson D, Lin L. Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy. Cytometry Part A 2019, 97: 70-77. PMID: 31411813, PMCID: PMC7004076, DOI: 10.1002/cyto.a.23869.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR mutationsGrowth factor receptor tyrosine kinase inhibitorsDrug resistanceReceptor tyrosine kinase inhibitorsEGFR TKI-resistant cellsEGFR-TKI resistanceNew treatment strategiesGefitinib-induced apoptosisAnti-cancer effectsLower survival rateWestern blot analysisMonths treatmentMost patientsNSCLC patientsCell cycle arrestTreatment strategiesHigh incidenceMortality rateSurvival rateCancer leadFlow cytometryPatientsResistant cellsKinase inhibitors
2017
Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action
Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action. International Journal Of Molecular Sciences 2017, 18: 656. PMID: 28304343, PMCID: PMC5372668, DOI: 10.3390/ijms18030656.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisDrug Resistance, NeoplasmDrugs, Chinese HerbalHumansConceptsAnti-cancer agentsNatural compound mixturesTherapeutic benefitCancer progressionCancer cellsSynergistic therapeutic benefitsPotential molecular targetsPositive therapeutic benefitsAberrant apoptotic pathwaysClinical efficacyTreatment of cancerAdverse reactionsCancer managementMerit further investigationMultiple specific targetsDrug resistanceCancerGenetic abnormalitiesEffective dosageLimited evidenceMolecular targetsScientific evidenceApoptotic mechanismsFurther investigationProgression
2016
Identification of candidate anti-cancer molecular mechanisms of compound kushen injection using functional genomics
Qu Z, Cui J, Harata-Lee Y, Aung TN, Feng Q, Raison JM, Kortschak RD, Adelson DL. Identification of candidate anti-cancer molecular mechanisms of compound kushen injection using functional genomics. Oncotarget 2016, 7: 66003-66019. PMID: 27602759, PMCID: PMC5323210, DOI: 10.18632/oncotarget.11788.Peer-Reviewed Original ResearchConceptsCompound Kushen InjectionAnti-cancer molecular mechanismMolecular mechanismsHigh-throughput Illumina RNA-Seq technologyIllumina RNA-Seq technologyMCF-7 cellsKushen InjectionRNA-seq technologyEffect of CKITranscriptome analysis methodsLong non-coding RNAsPlant secondary metabolitesNon-coding RNAsDifferential expression analysisCell proliferationGene differential expression analysisMCF-7 human breast cancer cell lineDe novo identificationHuman breast cancer cell linesMCF-7 cell proliferationBreast cancer cell linesDose-dependent fashionAnnexin V/propidium iodideTraditional Chinese medicine preparationP53-independent mechanism